AU Patent

AU2025271332A1 — Use of cannabinoids in the treatment of epilepsy

Assigned to Jazz Pharmaceuticals Research UK Ltd · Expires 2025-12-18 · 0y expired

What this patent protects

1006264938 The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous S…

USPTO Abstract

1006264938 The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis 5 Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). 5 1006264938 20 25 27 13 32 26 N ov 2 02 5 2 0 2 5 2 7 1 3 3 2 2 6 N o v 2 0 2 5 5 1 0 0 6 2 6 4 9 3 8

Drugs covered by this patent

Patent Metadata

Patent number
AU2025271332A1
Jurisdiction
AU
Classification
—
Expires
2025-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Research UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.